WEBULL
WebtradeDownload

NeoGenomics (NEO) Q3 Results Show Margin Gains Beneath A Flat Stock Price

Simply Wall St · 2d ago

NeoGenomics stock barely flinched after its Q3 2026 report, slipping 0.3% to US$17.93 despite a week of gains and a mixed month behind it. The market reaction looked sleepy. The earnings print did not.

The real story sat in the lab results, not the ticker tape. NeoGenomics delivered US$209.3m in Q3 revenue and stronger adjusted gross profitability, driven by double digit growth in next generation sequencing and a lift in average revenue per test. Short term traders saw a flat chart. Long term holders saw a business model starting to flex.

If you like the NeoGenomics test growth story but prefer businesses that combine strong diagnostics demand with sturdier balance sheets and cash flows, explore our screener of list of solid balance sheet and fundamentals stocks (22 results)

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): US$209.3m vs. US$187.8m (up about 11%)
  • Net Income/Loss (Q3 2026 vs Q3 2025): loss of US$7.5m vs. loss of US$27.1m (loss narrowed by about 72%)
  • Basic EPS (Q3 2026 vs Q3 2025): loss of US$0.06 per share vs. loss of US$0.21 per share (per share loss improved by about 72%)
  • Trailing 12-Month Revenue (Q3 2026 TTM vs Q3 2025 TTM): US$787.8m vs. US$709.2m (up about 11%)

Tired of squinting at dense tables and long lists of earnings figures? Get a clear visual read on NeoGenomics valuation, growth trends and key drivers in the full company report for NeoGenomics.

NasdaqCM:NEO Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
NasdaqCM:NEO Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

NeoGenomics Bull Case: High‑Value Testing Starts To Show

Supporters argue NeoGenomics is building a higher value testing platform that can scale profitably.

"Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth."

Q3 points in that direction. Adjusted gross margin widened by about 300 bps to roughly 49%, adjusted EBITDA reached about US$19m, and full year EBITDA guidance nudged up to around US$60m. NGS revenue growth of 29% with higher average revenue per test shows the mix is tilting toward the higher margin menu this narrative rests on.

NeoGenomics Bear Case: Nonclinical Drag And Fixed Costs

The bear worry is that weakness in pharma work and a heavy cost structure will blunt all that progress.

"The company's heavy investment in IT, laboratories, and digital infrastructure, coupled with a high fixed cost base, could compress net margins or lead to losses if revenue growth or test volumes underperform regional or industry expectations, especially as industry trends shift toward decentralized or point-of-care testing models that may erode NeoGenomics' centralized lab advantage."

There is some support for that concern. The business still reported a net loss of US$7.5m in Q3 and nonclinical revenue fell about 10% to roughly US$15m. Yet double digit clinical and NGS growth, plus raised revenue and EBITDA guidance, suggests fixed costs are being absorbed better than feared, at least for now.

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.

Hunt Quiet Disconnects In Plain Sight

NeoGenomics just showed how a busy income statement can coexist with a muted share price. The real opportunity could sit in stocks where fundamentals and current market expectations are out of sync.

  • Company 1 - 26% below our estimate - builds a low cost digital bank focused on rising customer activity and efficiency metrics.
  • Company 2 - 46% below our estimate - turns a recommender system into an AI engine predicting what users want to see and buy.
  • Company 3 - 43% below our estimate - sells large format digital displays and software into projects upgrading scoreboards, transit systems and youth sports facilities.

That is three of the list. See the full list of 30 companies trading below our fair value estimates →